Cargando…
48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221003/ http://dx.doi.org/10.1186/1471-2334-14-S2-P72 |
| _version_ | 1782342827973279744 |
|---|---|
| author | Yazdanpanah, Y Khuong-Josses, M-A Hocqueloux, L Pialoux, G Durant, J Wynne, B Granier, C Tebas, P Pappa, K Min, S |
| author_facet | Yazdanpanah, Y Khuong-Josses, M-A Hocqueloux, L Pialoux, G Durant, J Wynne, B Granier, C Tebas, P Pappa, K Min, S |
| author_sort | Yazdanpanah, Y |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4221003 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42210032014-11-10 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial Yazdanpanah, Y Khuong-Josses, M-A Hocqueloux, L Pialoux, G Durant, J Wynne, B Granier, C Tebas, P Pappa, K Min, S BMC Infect Dis Poster Presentation BioMed Central 2014-05-23 /pmc/articles/PMC4221003/ http://dx.doi.org/10.1186/1471-2334-14-S2-P72 Text en Copyright © 2014 Yazdanpanah et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Yazdanpanah, Y Khuong-Josses, M-A Hocqueloux, L Pialoux, G Durant, J Wynne, B Granier, C Tebas, P Pappa, K Min, S 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial |
| title | 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial |
| title_full | 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial |
| title_fullStr | 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial |
| title_full_unstemmed | 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial |
| title_short | 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial |
| title_sort | 48 week bone marker changes with dolutegravir (dtg) plus abacavir/lamivudine (abc/3tc) vs. tenofovir/emtricitabine/efavirenz (efv/tdf/ftc): the single trial |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221003/ http://dx.doi.org/10.1186/1471-2334-14-S2-P72 |
| work_keys_str_mv | AT yazdanpanahy 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT khuongjossesma 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT hocquelouxl 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT pialouxg 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT durantj 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT wynneb 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT granierc 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT tebasp 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT pappak 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial AT mins 48weekbonemarkerchangeswithdolutegravirdtgplusabacavirlamivudineabc3tcvstenofoviremtricitabineefavirenzefvtdfftcthesingletrial |